Life Sciences weekly highlights—29 January 2026
This week's edition of Life Sciences weekly highlights includes several analyses: analysis by Lexis+ that discusses what the key developments were for life sciences lawyers in 2025 and looks ahead to what is coming in 2026 in the UK, analysis of the Court of Appeal allowing Abbott’s appeal and overturning the revocation of its European (UK) patent for a continuous glucose monitoring (CGM) device, and a Law360 analysis of regulators in the US and EU jointly releasing a set of agreed-upon principles intended to guide the use of AI in drug development. Also included is news that the MHRA has updated a suite of guidance in support of its Innovative Licensing and Access Pathway (ILAP), and has formally assumed the role of chair of the Access Consortium for 2026, succeeding Swissmedic, the Patents Court ruled on case management matters in patent revocation and infringement proceedings in Merck Sharp & Dohme (UK) Ltd v Halozyme Inc, as well as news that the Commission launched a public consultation on the evaluation of EU plant variety rights legislation and the MHRA has published guidance to help users assess digital mental health technologies (DMHTs), among other stories.